Urine and serum concentrations of Cytokeratin 19 in preeclampsia

Kuessel, Lorenz; Wild, Julia; Haslacher, Helmuth; Perkmann, Thomas; Ristl, Robin; Zeisler, Harald; Schmid, Maximilian

doi:10.1016/j.ejogrb.2014.08.020

Cited by 3 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously studied the role of CYFRA 21–1 in PE and found significantly higher levels of CYFRA 21–1 in the serum of 32 preeclamptic women compared to 32 matched controls [20]. Our current results, which are based on a larger number of cases, support this previous finding.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

The usefulness of CYFRA 21–1 to diagnose and predict preeclampsia: a nested case-control study

Kuessel

Zeisler

Ristl

et al. 2016

BMC Pregnancy Childbirth

Self Cite

View full text Add to dashboard Cite

BackgroundThe ability to identify patients at risk for developing preeclampsia is important for preventing morbidity and mortality in both the mother and child. Although CYFRA 21–1 (a fragment of Cytokeratin 19) is considered a promising biomarker for diagnosing preeclampsia, little is known regarding the levels of CYFRA 21–1 during pregnancy. Here, we measured serum CYFRA 21–1 levels in women with an uneventful pregnancy and in women whose pregnancy was complicated by preeclampsia. Furthermore we evaluated whether maternal CYFRA 21–1 levels can be used to predict and/or diagnose preeclampsia.MethodsLongitudinal, sequential blood samples were collected prospectively at seven predetermined visits during pregnancy. Maternal CYFRA 21–1 levels were measured in 50 women with an uneventful pregnancy (control group) and in 10 asymptomatic women whose pregnancy was later complicated by preeclampsia (PE_long group). In addition, CYFRA 21–1 levels were measured from a single sample collected from a separate group of 50 pregnant women with symptomatic preeclampsia (PE_state group).ResultsThe CYFRA 21–1 levels were significantly higher in the PE_state group compared to the control group (p < 0.001). In the PE_long group, CYFRA 21–1 levels were lower from gestational week 11 through 17, but were higher than the control group from gestational weeks 18 through 36.Out of the ROC curves that were calculated to investigate the predictive and diagnostic properties of CYFRA 21–1 levels for preeclampsia, the ROC curve for diagnosing preeclampsia in gestational week 28–32 showed the largest AUC of 0.92, at a cut-off point of 3.1 ng/ml, leading to sensitivity of 92 % and specificity of 80 %.ConclusionsThe elevated serum levels of CYFRA 21–1 observed in both groups of women with preeclampsia may reflect endothelial damage and/or dysfunction. Our results suggest that maternal serum CYFRA 21–1 is a promising biomarker for diagnosing preeclampsia. Although its value for predicting the long-term occurrence of subsequent preeclampsia may be limited, our findings indicate a trend towards elevated maternal CYFRA 21–1 levels preceding the short-term occurrence of preeclampsia in asymptomatic women. Additional prospective longitudinal studies are needed in order to determine the value of measuring maternal serum CYFRA 21–1 in predicting preeclampsia.

show abstract

Section: Discussionsupporting

confidence: 89%

“…Furthermore, serum CYFRA 21–1 levels have associated with disease severity and appear to be unaffected by antihypertensive medications [19, 20]. However, little is known regarding the dynamics of CYFRA 21–1 during pregnancy, regardless of whether the pregnancy is uneventful or complicated by PE.…”

Section: Introductionmentioning

confidence: 99%

The usefulness of CYFRA 21–1 to diagnose and predict preeclampsia: a nested case-control study

Kuessel

Zeisler

Ristl

et al. 2016

BMC Pregnancy Childbirth

Self Cite

View full text Add to dashboard Cite

show abstract

“…False positives for CYFRA 21-1 may occur in patients with kidney failure [154], particularly in those receiving peritoneal dialysis; values above the URL were recorded in 73% of these patients, and in 57% of patients with hemodialysis [155]. Elevated levels of CYFRA 21-1 have also been observed in patients with diabetic nephropathy [156], benign pleural and pericardial effusions [157], cirrhosis of the liver and preeclampsia, where levels were related to the severity of the disease [158]. In the case of SARS-CoV-2 infection, Wei et al [159] observed values above the URL.…”

Section: Chromogranin a (Cga)mentioning

confidence: 99%

Factors influencing blood tumor marker concentrations in the absence of neoplasia

Trapé,

Fernández-Galán,

Auge

et al. 2024

TUB

View full text Add to dashboard Cite

BACKGROUND: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce the synthesis of TMs, and the release of these molecules into the bloodstream allows their quantification in biological fluids. Although very small concentrations of TMs are usually present in the serum or plasma of healthy subjects, increased concentrations may also be found in the presence of benign diseases or due to technical interference, producing false positive results. MATERIAL AND METHODS AND RESULTS: Our review analyses the causes of false positives described between January 1970 to February 2023 for the TMs most frequently used in clinical practice: α-fetoprotein (AFP), β2-microglobulin (β2-M), cancer antigen 15-3 (CA 15-3), cancer antigen CA 19-9 (CA 19-9), cancer antigen CA 72-4 (CA 72-4), cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), chromogranin A (CgA), choriogonadotropin (hCG), cytokeratin 19 fragment (CYFRA 21-1), neuron-specific enolase (NSE), human epididymis protein 4 (HE4), serum HER2 (sHER2), squamous cell carcinoma antigen (SCCA), protein induced by vitamin K absence-II (PIVKA-II), Pro-gastrin-releasing peptide (Pro-GRP), prostate-specific antigen (PSA), Protein S-100 (S-100) and thyroglobulin (Tg). A total of 247 references were included. CONCLUSIONS: A better understanding of pathophysiological processes and other conditions that affect the concentration of TMs might improve the interpretation of results and their clinical application.

show abstract

Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples

et al. 2017

View full text Add to dashboard Cite

Phthalocyanine-BODIPY dye (BODIPY = boron dipyrromethene) was synthesized, fully characterized, and used for molecular recognition of CYFRA 21-1, a lung cancer biomarker, from whole blood samples. Thin films of three magnesium oxides ((MgO) , where n = 8, 9, or 10)) were deposited on a paper substrate, and they were immersed in a solution of phthalocyanine-BODIPY dye (1.17 × 10 mol/L) for the design of stochastic sensors. Limits of determination of picograms per milliliter magnitude order were recorded for the proposed stochastic sensors. CYFRA 21-1 was reliably identified and determined with recoveries higher than 95% and RSD lower than 1% in whole blood samples.

show abstract

Urine and serum concentrations of Cytokeratin 19 in preeclampsia

Cited by 3 publications

References 27 publications

The usefulness of CYFRA 21–1 to diagnose and predict preeclampsia: a nested case-control study

The usefulness of CYFRA 21–1 to diagnose and predict preeclampsia: a nested case-control study

Factors influencing blood tumor marker concentrations in the absence of neoplasia

Phthalocyanine-BODIPY dye: synthesis, characterization, and utilization for pattern recognition of CYFRA 21-1 in whole blood samples

Contact Info

Product

Resources

About